Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide dose-escalation and expansion study in relapsed or refractory multiple myeloma
2024-510799-19-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (9 cohorts), sponsored by Celgene Corporation. Primary endpoints: Maximum tolerated dose and/or recommended Phase 2 dose and Overall response rate in Cohort D. Planned start Aug 2016; status: authorised.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-510799-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510799-19-00.